MUCOSTA Tablet

គុណភាពព្យាបាល
ឱសថនេះប្រើសំរាប់ព្យាបាល៖
- ជម្ងឺដំបៅក្រពះ
- ជម្ងឺរលាកភ្នាសក្រពះ (រហែក ហូរឈាម ឡើងក្រហម និង ហើម)ដែលមានសភាពរលាកធ្ងន់ធ្ងរនិងរ៉ាំរ៉ៃ។
កម្រិតនិងរបៀបប្រើ
- ជម្ងឺដំបៅក្រពះ៖ មនុស្សពេញវ័យ លេបម្ដង1គ្រាប់ លេប3ដងក្នុង1ថ្ងៃ ព្រឹក ល្ងាច និងមុនចូលដេក។
- ជម្ងឺរលាកក្រពះធ្ងន់ធ្ងរនិងរ៉ាំរ៉ៃ៖ លេបម្ដង1គ្រាប់ (100ម.ក្រ) លេប3ដងក្នុង1ថ្ងៃ។

1. Gastric ulcers

2. Treatment of gastric mucosal lesions (erosion, bleeding, redness and edema) in the following conditions: acute gastritis and acute exacerbation of chronic gastritis

Dose & mode of administration

1. Gastric ulcers: 1tablet taken by the oral route three times daily, in the morning, in the evening, and before at bedtime.

2. Treatment of gastric mucosal lesions (erosion, bleeding, redness and edema) in the following conditions: 1 tablet three times taken by the oral route.

ហាមប្រើចំពោះអ្នកជម្ងឺមានប្រវត្តិងាយប្រតិកម្មជាមួយសារធាតុផ្សំណាមួយនៃឱសថនេះ។

Patients with a history of hypersensitivity to any ingredient of this drug.

No drug interactions are reported.

ចំពោះស្ត្រីមានផ្ទៃពោះ និងស្ត្រីបំបៅកូន មុនប្រើឱសថនេះ ត្រូវពិគ្រោះជាមួយគ្រូពេទ្យ។

Rebamipide should only be administered to pregnant or possibly pregnant women if the anticipated therapeutic benefit is thought to outweigh any potential risk. The safety of this drug in pregnant women has not been established.

Rebamipide is reported to be transferred to the milk in lactating rats. Breast-feeding should be interrupted before rebamipide is administered.

ការប្រុងប្រយ័ត្ន៖
- ចំពោះអ្នកជម្ងឺដែលមានវ័យចំណាស់ ព្រោះឱសថនេះអាចបណ្ដាលអោយមានវិបត្តិក្រពះ ពោះវៀន។
- ចំពោះកុមារ ស្ត្រីមានផ្ទៃពោះ និងស្ត្រីបំបៅកូន មុនប្រើឱសថនេះ ត្រូវពិគ្រោះជាមួយគ្រូពេទ្យ
- ចំពោះអ្នកដែលមានប្រតិកម្មជាមួយសារធាតុផ្សំណាមួយនៃឱសថនេះ
- ចំពោះអ្នកជម្ងឺដែលប្រើឱសថនេះមានកើតឡើងនូវប្រតិកម្មឬរោគសញ្ញាផ្សេងៗ ត្រូវបញ្ឈប់ឬបន្ថយកំរិតប្រើទៅតាមសភាពជម្ងឺ។

1. WARNINGS

Leucopenia, thrombocytopenia, hepatic dysfunction, jaundice (incl. AST/ALT increased) have been reported in post-marketing spontaneous reporting scheme. Although no notable trend in the nature of these events are observed, due care should be paid in patients receiving oral MUCOSTA Tablets. If abnormal findings suggestive of three reactions are observed, the drug should be discontinued and appropriate measures taken. Patients under long-term use of MUCOSTA Tablets should be monitored periodically for any signs or symptoms of elevated liver enzymes, decreased white blood cell count and/or platelet count.

2. PRECAUTIONS

(1) Use in the Elderly

Special care is required in elderly patients to minimize the risk of gastrointestinal disorders, because these patients may be physiologically more sensitive to this drug than younger patients.

(2) Pediatric Use

The safety of this drug in low birth weight infants, newborns, suckling infants, infants and children has not been established. (Clinical experience is insufficient.)

1. Preventive or healing effects in gastric ulcer models

2. Preventive or healing effects in gastritis models

3. Prostaglandin-increased effect

4. Cytoprotective effect

5. Mucus-increasing effect

6. Mucosal blood flow-increasing effect

7. Effect on mucosal barrier

8. Effect on gastric alkaline secretion

9. Effect on mucosal cell turnover

10. Effect on gastric mucosal repair

11. Effect on gastric secretion

12. Effect on oxygen free-radicals

13. Effect on inflammatory cell infiltration in the gastric mucosa

14. Effect on inflammatory cytokine release (interleukin-8) in the gastric mucosa